Extended immunotherapy shows promise for tough prostate cancer

This early-phase trial is testing whether giving an extra dose of the immunotherapy drug Sipuleucel-T can strengthen the immune system's attack on prostate cancer that has spread and stopped responding to hormone therapy. Fifteen men with this advanced cancer will receive three infusions over about 14 weeks instead of the usual two. Researchers will measure immune responses and check if the extended schedule is practical and safe.